SCHEMBL30593153

SCHEMBL30593153

Cc1cc(OCc2ccccc2)cc(-c2cc(C(F)(F)F)cnc2Cl)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.43
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
FFAR4 Q5NUL3 1/20 0.40
MRGPRX4 Q96LA9 1/20 0.39
PDE10A Q9Y233 1/20 0.39
RAF1 P04049 2/20 0.39
BRAF P15056 2/20 0.39
TDP1 Q9NUW8 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
HDAC1 Q13547 1/20 0.38
HDAC8 Q9BY41 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38
HDAC5 Q9UQL6 1/20 0.38
GLA P06280 1/20 0.36
CRHR1 P34998 1/20 0.36
PSEN1 P49768 1/20 0.36
PSEN2 P49810 1/20 0.36
APH1B Q8WW43 1/20 0.36
NCSTN Q92542 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26608223 1.00 ALDH1A1 (0.43) ALDH1A1MEN1KMT2AFFAR4MRGPRX4
SCHEMBL26608363 1.00 ALDH1A1 (0.43) ALDH1A1MEN1KMT2AFFAR4MRGPRX4
SCHEMBL26608380 0.81 HDAC1 (0.41) ALDH1A1MEN1KMT2AMRGPRX4RAF1
SCHEMBL30593187 0.81 HDAC1 (0.41) ALDH1A1MEN1KMT2AMRGPRX4RAF1
SCHEMBL31336252 0.81 HDAC1 (0.41) ALDH1A1MEN1KMT2AMRGPRX4RAF1
SCHEMBL26608475 0.81 HDAC1 (0.41) ALDH1A1MEN1KMT2AMRGPRX4RAF1
SCHEMBL31336268 0.77 HTT (0.49) ALDH1A1MEN1KMT2AL3MBTL1HPGD
SCHEMBL26608303 0.77 HTT (0.49) ALDH1A1MEN1KMT2AL3MBTL1HPGD
SCHEMBL26608459 0.76 RAF1 (0.34) ALDH1A1MEN1KMT2AFFAR4RAF1
SCHEMBL15984861 0.72 ALOX5 (0.56) MEN1KMT2ATDP1L3MBTL1HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250388543-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN VERTEX PHARMACEUTICALS INCORPORATED (US) 2025-12-25 US disclosed
CN-119546580-A Heteroaryl compounds for the treatment of pain 沃泰克斯药物股份有限公司 2025-02-28 CN disclosed
EP-4511115-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN Vertex Pharmaceuticals Incorporated (US) 2025-02-26 EP disclosed
WO-2023205468-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-10-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250388543-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN SCN8A, SCN1B, SCN3A ALDH1A1 2279/4885MEN1 4387/4885KMT2A 3307/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.